Chinese Pharmaceutical Companies Achieve Multiple Breakthroughs in Pediatric Therapeutics in 2026, Spanning Vaccines and Medical Devices

　　【Pharmaceutical Network Industry DynamicsSince 2026, pharmaceutical companies in China have made multiple breakthroughs in the pediatric field, covering various areas such as vaccines, improved new drugs, high-end first-to-market generics, and medical devices.
 

Recently, BrioHealth Solutions, the wholly-owned U.S. subsidiary of BrioHealth Solutions, announced that it has received conditional approval from the U.S. Food and Drug Administration (FDA) to initiate clinical evaluation of the BrioVAD® system for pediatric patients with advanced heart failure.
 

It is reported that BrioVAD® is an entirely new product developed by BrioHealth Solutions based on its commercially available CH-VAD. It is the first active implantable medical device in China to receive approval from the U.S. FDA for clinical trials. Compared with similar international products, this device is smaller in size, lighter in weight, and thinner in profile, causing less blood damage and fewer complications such as hemolysis and thrombosis. Currently, the INNOVATE clinical trial of BrioVAD® for adults has completed enrollment of over 150 patients across multiple top clinical centers in the United States, with more than 100 cases of BrioVAD® system implants performed.
 

In April, the infant adsorbed acellular pertussis (three-component) diphtheria and tetanus combined vaccine — PanKangXin® independently developed by CanSinoBIO was officially approved. As the first three-component DTP vaccine approved in China, it contains three key antigens: PT (pertussis toxin), FHA (filamentous hemagglutinin), and PRN (pertactin), covering multiple immune targets related to pertussis.
 

Phase III clinical trial results show that Pankangxin® demonstrates a stronger immune response after primary vaccination in 2-month-old infants. Compared with the control group, the vaccine achieved superior primary immunization efficacy against the PT antigen. Additionally, this vaccine contains no thimerosal, antibiotics, or animal-derived components, ensuring a pure formulation. The incidence of fever following booster immunization was reduced by more than 50%, and the vaccine exhibited excellent safety and tolerability.
 

In March, Guizhou Bailing Group Pharmaceutical Co., Ltd. announced that the company had received the "Drug Supplemental Application Approval Notice" issued by the National Medical Products Administration, approving the expansion of the main treatment population for Compound Yizhihuanghua Spray to include "children aged 6-13" for acute pharyngitis.
 

Compound Yizhihuanghua Spray is a key Miao medicine product developed by Guizhou Bailing Group Pharmaceutical Co., Ltd. It is made from seven medicinal herbs, including Yizhihuanghua, Shan Yin Hua, and Ziqi Guanzhong, and is used for symptoms such as upper respiratory tract infections, acute and chronic pharyngitis, mouth ulcers, swollen gums, and bad breath.
 

In February, Trinomab's core product, recombinant long-acting anti-respiratory syncytial virus (RSV) fully human monoclonal antibody – Retvebimab Injection, has submitted a new drug application and been accepted, and has been included in the priority review process.
 

According to its Phase III clinical study, it significantly reduced the incidence of RSV lower respiratory tract infections within 150 days after administration in healthy full-term infants and late preterm infants, with particularly outstanding preventive protection against severe RSV lower respiratory tract infections. A single intramuscular injection can cover the entire RSV season, offering convenience and high efficiency that meets the protective needs of infants.
 

　　……
 

Overall, with the normalization of the expedited review and approval channel, along with enterprises' continuous investment in child-friendly formulations and original innovation, the "golden age" of pediatric medication in China will accelerate. By 2026, it is expected that numerous companies will unveil new achievements in domestically produced drugs and medical devices within the pediatric field.
 

　　Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice to any person.